Key statistics
On Thursday, Enlivex Therapeutics Ltd (ENLV:TLV) closed at 547.30, 23.24% above the 52 week low of 444.10 set on Aug 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 551.40 |
---|---|
High | 592.90 |
Low | 535.10 |
Bid | 550.00 |
Offer | 551.90 |
Previous close | 541.20 |
Average volume | 37.71k |
---|---|
Shares outstanding | 21.41m |
Free float | 18.76m |
P/E (TTM) | -- |
Market cap | 31.25m USD |
EPS (TTM) | -1.19 USD |
Data delayed at least 20 minutes, as of Sep 26 2024 15:24 BST.
More ▼
- Enlivex Receives Authorization from the Danish Medicines Agency to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
- Enlivex Announces Positive DSMB Recommendation to Initiate the Phase II Stage of its Phase I/II Trial of Allocetra in Patients with Moderate to Severe Knee Osteoarthritis
- Enlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic Arthritis
- Enlivex Announces the Dosing of the First Patient in a Randomized, Placebo-Controlled Phase I/II Trial Evaluating AllocetraTM in up to 46 Patients with Thumb Osteoarthritis
- Join Enlivex Therapeutics’ Chief Executive Officer for a Live Investor Webinar and Q&A Session on June 25
- Enlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee Osteoarthritis
- Enlivex Receives Regulatory Authorization for the Initiation of a Placebo-Controlled Phase I/II Trial Evaluating Allocetra in Up To 46 Patients with Thumb Osteoarthritis
- Enlivex Therapeutics Closes up to $15 Million Registered Direct Offering
- Enlivex Therapeutics Announces up to $15 Million Registered Direct Offering
- Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events
More ▼